Clinical Trials Directory

Trials / Completed

CompletedNCT06410729

Significance of Benign Lymph Node Enlargement in Colorectal Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
2,270 (actual)
Sponsor
Peking University Third Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The objective of this observational study was to investigate the clinical significance of benign mesenteric lymph node (BLNE) enlargement in patients with colorectal cancer. The main questions it aims to answer are: Do patients with benign mesenteric lymph node enlargement have a better prognosis? What are the clinical characteristics of benign mesenteric lymph node enlargement? As part of routine medical care for colorectal cancer, we will follow up with all participants over the course of the study.

Detailed description

From January 2015 to June 2023, 2,270 patients with colorectal cancer received surgical treatment at Peking University Third Hospital. The clinical data of these patients were recorded retrospectively and the eligible patients were divided into two groups. According to the 9th edition of the TNM staging System published by the AJCC, the BLNE group included the mesenteric BLNE group, while the non-benign lymph node enlargement (NBLNE) group was the control group. Inclusion criteria were :1) No regional lymph node metastasis or distant metastasis; 2) Stage I and II patients with AJCC staging system; 3) Radical CRC resection reached R0 status, no positive lymph nodes; Colonoscopy confirmed a single malignant lesion. Exclusion criteria :1) emergency surgery or preoperative complications such as intestinal obstruction and perforation; 2) Positron emission tomography (PET-CT) suspected distant metastasis; 3) Preoperative neoadjuvant therapy; 4) Hereditary colorectal cancer such as familial adenomatous polyposis; Microsatellite instability (MSI) was confirmed by pathology. In early colorectal cancer, MSI-H status is associated with a favorable prognosis and enhanced anti-tumor immune response. Therefore, we excluded these patients to avoid their influence on prognosis. 6) Lack of imaging data; 7) Loss of follow-up.

Conditions

Interventions

TypeNameDescription
OTHERObservational study, no intervention

Timeline

Start date
2015-01-01
Primary completion
2023-06-30
Completion
2023-06-30
First posted
2024-05-13
Last updated
2024-05-14

Source: ClinicalTrials.gov record NCT06410729. Inclusion in this directory is not an endorsement.